MAR 18, 2016 8:44 AM PDT

Infrared Sensor for the Detection of Alzheimer from Blood

WRITTEN BY: Xuan Pham
New patented diagnostic method for Alzheimer's detection

In the past several months, researchers have been focusing on easier point-of-care tests that offer early detection of diseases. One such test was recently proposed for Alzheimer’s disease, based on the idea of a portable biosensor that will diagnose disease progression by measuring beta-amyloid protein levels in the blood. However, such test has already been developed in Germany, and researchers recently reported 84 percent diagnostic precision from their first clinical trial.
 
The newly patented diagnostic test was developed by a research team at the Ruhr-University Bochum in Germany. Instead of just measuring levels of the beta-amyloid proteins, a signature of Alzheimer’s, the new test uses an infrared sensor that detects pathological misfolding of the protein. The presence of such misfolded proteins can occur more than 15 years before symptoms appear in the patients, and thus offer unprecedented early detection for the disease.
 
To assay beta-amyloid misfolding, the new test uses specific antibodies to attract protein biomarkers from cerebrospinal fluid samples or blood samples. The patent-pending infrared technology then scans the proteins for the presence and total distribution of secondary structures. Unlike other enzyme-linked immunosorbent assays (ELISA) that give the concentrations of abnormally folded proteins, the new test gives information on the distribution of the secondary structures, which could offer higher precision.
 
 "We do not merely select one single possible folding arrangement of the peptide; rather, we detect how all existing Amyloid beta secondary structures are distributed, in their healthy and in their pathological forms," said Klaus Gerwert, senior study author.
 
In a small clinical trial of 141 patients, the new test achieved a diagnostic precision of 84 percent in the blood and 90 per cent in cerebrospinal fluid. "What's unique about it is that this is the only robust label-free test with a single threshold," said Andreas Nabers, first study author.
 
Alzheimer’s disease is highly prevalent, accounting for over 7 million new cases every year. While there’s no cure yet, the detection and early diagnosis of the disease could influence patient care and outcome. According to the study authors, current diagnosis for the disease comes too late, as severe irreversible brain damages have already occurred in the time it takes for clinical symptoms to manifest. "If we wish to have a drug at our disposal that can significantly inhibit the progress of the disease, we need blood tests that detect Alzheimer's in its pre-dementia stages," said Gerwert. In catching Alzheimer early, researchers could have the rare opportunity to administer drugs to possibly prevent, or at the very least, delay its progression.
 

Additional source:  Ruhr-Universität Bochum press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 11, 2020
Clinical & Molecular DX
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
AUG 11, 2020
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
The human body is made up of around 10 trillion cells. Fascinatingly, we have 10 times more bacterial cells on our bodie ...
AUG 15, 2020
Cardiology
Following Platelets to Diagnose Myocarditis
AUG 15, 2020
Following Platelets to Diagnose Myocarditis
The heart is a sensitive thing, prone not just to metaphorical heartbreak, but genuine issues if not taken care of. Myoc ...
SEP 16, 2020
Cancer
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
SEP 16, 2020
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
The last decade has seen the emergence of several new therapies against cancer. For melanoma, checkpoint inhibitors have ...
OCT 27, 2020
Clinical & Molecular DX
A Super Sensitive Alzheimer's Test Powered by Nanozymes
OCT 27, 2020
A Super Sensitive Alzheimer's Test Powered by Nanozymes
  Simple tasks are now uphill struggles, social situations aren’t fun, and the car keys are missing again. By ...
OCT 24, 2020
Clinical & Molecular DX
Software Flags Elevated Cerebral Palsy Risk in Premies
OCT 24, 2020
Software Flags Elevated Cerebral Palsy Risk in Premies
Diagnostic imaging scientists have developed a software tool for predicting the future onset of cerebral palsy in babies ...
NOV 07, 2020
Neuroscience
Device Measures Stress Hormones with Earwax
NOV 07, 2020
Device Measures Stress Hormones with Earwax
Researchers from University College London and King’s College London in the UK have developed a device that can me ...
Loading Comments...